-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vir Biotech has launched a new antibody research initiative, expanding its partnership with the Bill & Melinda Gates Foundation , including advancing new treatments for HIV and malaria treatments
.
A new commitment from the Bill & Melinda Gates Foundation supports the development of Vir Biotech's "vaccine antibody" technology, an important tool in the fight against infectious diseases worldwide
.
Vir Biotech's antibody research program aims to achieve a functional cure for HIV and prevention
prevention
The expansion of Vir Biotech's partnership with the Foundation will include advances in innovative platform technology to develop "broadly neutralizing antibodies
.
" These antibodies are designed to provide a "vaccine effect" for treating HIV and preventing malaria
immunity
Mike McCune, director of the Gates Foundation's HIV Frontiers Program, explained: "Even for those with access to effective antiretroviral treatment, HIV has gone from a recently fatal disease to a chronic one, but it is not a problem for those with access to effective antiretroviral therapy.
There remains a huge unmet need for new advances in durable antiretroviral-free suppression of HIV
.
"
To support this effort, the Gates Foundation has committed $40 million in equity investments and $10 million in grants
.
The program will assess the potential impact of broadly neutralizing antibodies
To support this effort, the Gates Foundation has committed $40 million in equity investments and $10 million in grants
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a comment here